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Free fatty acids (FFAs) are essential nutrients and act as signaling molecules in various
cellular processes via binding with FFA receptors. Of these receptors, GPR43 is activated
by short-chain fatty acids (SCFAs; e.g., acetate, propionate, and butyrate). During feed-
ing, SCFAs are produced by microbial fermentation of dietary fiber in the gut, and these
SCFAs become important energy sources for the host. The gut microbiota affects nutrient
acquisition and energy regulation of the host and can influence the development of obe-
sity, insulin resistance, and diabetes. Recently, GPR43 has been reported to regulate host
energy homeostasis in the gastrointestinal tract and adipose tissues. Hence, GPR43 is
also thought to be a potential drug target for metabolic disorders, such as obesity and dia-
betes. In this review, we summarize the identification, structure, and activities of GPR43,
with a focus on host energy regulation, and present an essential overview of our current
understanding of its physiological roles in host energy regulation that is mediated by gut
microbiota. We also discuss the potential for GPR43 as a therapeutic target.
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INTRODUCTION
Obesity is currently one of the most serious public health problems
worldwide because of its increasing prevalence and contribution to
serious metabolic disorders, including type-2 diabetes (1, 2). Obe-
sity is the result of a long-term imbalance between energy intake
and expenditure, and is therefore regulated by multiple pathways
involving metabolites, hormones, and neuropeptides (3). Excess
food intake, especially high-fat and sugar foods, and lack of phys-
ical activity are considered as risk factors in the developing of
obesity. Recent research has demonstrated that the gut microbiota
is involved in obesity and metabolic disorders (4, 5). An impor-
tant role of the gut microbiota is to catabolize substrates, such as
dietary fiber, that are not completely hydrolyzed by host enzymes
during host feeding (6). The main colonic bacterial fermentation
products of dietary fiber are short-chain fatty acids (SCFAs), such
as acetate, propionate, and butyrate (7). SCFAs can be used for de
novo synthesis of lipids and glucose, which are the main energy
sources for the host (8).
THE SCFA RECEPTOR GPR43
In addition to functioning as an energy source, SCFAs are also
essential nutrients that act as signaling molecules. Recently, two
orphan G-protein coupled receptors (GPCR), GPR41 and GPR43,
were reported to be activated by SCFAs. During ligand screen-
ing for bioactive compounds, researchers reported that GPR43,
also known as free fatty acid receptor 2 (FFAR2), was acti-
vated by acetate using Ca2+ assays in transfected cells (9, 10).
GPR43 can also be activated by other SCFAs, including propi-
onate and butyrate; acetate and propionate are the most effi-
cient for activating GPR43, followed by butyrate and then other
SCFAs (9, 11).
GPR43 is a dual-coupling GPCR that binds with the pertussis
toxin-sensitive Gi/o and Gq proteins (11). Stimulation of GPR43
by SCFAs inhibits cAMP production, activates the extracellu-
lar signal-regulated kinase (ERK) cascade via interactions with
the Gi/o family of G-proteins, increases intracellular Ca2+ levels,
and promotes activation of the mitogen-activated protein kinase
(MAPK) cascade via interactions with the Gq family of G-proteins.
However, the physiological significance of this GPR43-based dual-
coupled signaling mechanism is still unclear. GPR43 is expressed
in the adipose tissue, intestines, and immune tissues (12, 13). In the
immune system, many studies have investigated the role of GPR43
in regulating inflammatory responses (13–15). These results indi-
cate that GPR43 is important for gut immunity involving gut
microbiota and food. On the other hands, GPR43 expression in
adipose and gastrointestinal tissues suggests that GPR43 may be
involved in energy regulation (16); moreover, reverse transcription
polymerase chain reaction (RT-PCR) in mouse tissues has shown
that Gpr43 is expressed in white adipose tissue (WAT) and the
intestine (12).
ADIPOSE TISSUES
Adipose tissues are very important tissues associated with energy
homeostasis and energy accumulation. In adipose tissues, GPR43
may be involved in regulating obesity and energy accumulation,
Similarly, Gpr43 mRNA is expressed in WATs, including subcuta-
neous, perirenal, and epididymal tissues, as well as in 3T3-L1-
derived adipocytes and mature adipocytes (12). Based on the
observed expression of Gpr43 in adipose tissues and adipocytes,
Hong et al. performed a series of studies to elucidate the functions
of GPR43 in adipocytes (12). They showed that Gpr43 expression
was significantly greater in the WAT of mice with high-fat diet
(HFD)-induced obesity compared with normal chow-fed mice.
Moreover, in 3T3-L1 cells, treatment with SCFAs, increased Gpr43
and Pparg transcript levels, while suppression of Gpr43 mRNA by
RNA interference inhibited adipogenesis. Thus, SCFAs appear to
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promote adipogenesis via GPR43. Additionally, in 3T3-L1 derived
adipocytes, SCFAs suppress isoproterenol-induced lipolysis in a
concentration-dependent manner (12). Ge et al. demonstrated
that these effects are dependent on GPR43 using Gpr43-deficient
mice (17). That is, they showed that acetate suppressed lipoly-
sis, and release of glycerol occurred in a concentration-dependent
manner in adipocytes isolated from wild-type mice in vitro, and the
activation of GPR43 by intraperitoneal injection of sodium acetate
instantly reduced plasma fatty acid in vivo; these effects were abro-
gated in Gpr43-knockout mice (17). In brown adipose tissues
(BATs), which have a central role in the regulation of energy bal-
ance and homeostasis, Bjursell et al. reported thatGpr43-knockout
mice fed an HFD exhibited improved insulin sensitivity in old age
due to increased energy expenditure, which resulted in increased
body temperature (18). As a potential explanation for this, his-
tological observation of BAT in Gpr43-knockout mice revealed
that these mice exhibited decreased lipid dispersion compared
with wild-type mice fed an HFD. However, we could not detect
Gpr43 expression in BATs (19). Hence, further studies are needed
to elucidate the role of GPR43 in energy control via BAT.
Recent evidence suggests that the gut microbiota affects host
nutrient acquisition and energy regulation and is therefore related
to obesity, insulin resistance, and diabetes in the host (20–22).
During feeding, SCFAs, which act as ligands for GPR43, are
produced by microbial fermentation of dietary fiber in the gut.
Hence, we examined the relationship between gut microbiota
and systemic energy regulation by GPR43 in adipose tissue using
Gpr43-mutantand germ-free mice (19). In a series of in vitro
and in vivo studies, we found that Gpr43 deficiency induced
obesity in mice, while mice that overexpress Gpr43 only in adi-
pose tissues were lean under normal conditions; both of these
mouse strains did not exhibit either phenotype under germ-free
conditions or after antibiotic treatment. Furthermore, SCFA-
mediated GPR43 activation suppressed adipose insulin signal-
ing, leading to inhibition of fat accumulation in the adipose
tissue, and unincorporated lipids and glucose were primarily uti-
lized in muscles. That is, the expression of energy expenditure-,
glycolysis-, and beta-oxidation-related genes increased, while the
expression of gluconeogenesis-related genes decreased in the
muscles of aP2-Gpr43 TG mice. However, the mechanism by
which GPR43 mediated the suppression of insulin signaling in
adipocytes is not mediated by cAMP inhibition, but instead
involves the beta and gamma subunits of the Gi/o protein, not
Gq protein. Thus, GPR43 acts as a sensor for excessive dietary
energy, thereby controlling body energy utilization while main-
taining metabolic homeostasis. The GPR43-insulin pathway in
adipose tissue may function as an important physiological mech-
anism through which these metabolic fuels regulate body energy
balance. Hence, these previous reports in adipose tissues indi-
cate that GPR43 has potential therapeutic relevance for the
treatment of metabolic disorders, such as obesity and type-2
diabetes.
INTESTINAL TISSUES
In the intestines, GPR43 may be involved in regulating appetite
and insulin signaling. Indeed, Gpr43 mRNA has been shown to
be expressed in rat and human ileum and colon, especially in
FIGURE 1 | Under “fed” conditions, SCFAs are produced in the gut by
bacterial fermentation of dietary fiber. SCFAs alter the metabolic rate by
stimulating GPR43 in adipocytes and promote gut hormone secretion and
motility by stimulating GPR43 in the intestine, thereby increasing energy
expenditure and improving glucose tolerance to increase energy utilization.
enteroendocrine cells (23, 24). Like adipose tissue, the intestine
is also critical for energy homeostasis, as supported by its asso-
ciation with secretion of appetite gut hormones and nutrients
absorption (25, 26). Using immunohistochemistry analysis with
GPR43 antibodies in rats, Karaki et al. reported that GPR43 is
expressed in peptide YY (PYY)-containing enteroendocrine L-cells
of the gastrointestinal tract (23). Enteroendocrine L-cells are also
one of the major cell types that express the proglucagon genes
GLP-1 andGLP-2. GLP-1 and GLP-2 proteins are co-stored and co-
secreted with PYY from enteroendocrine L-cells (27), and SCFAs
are co-secreted with GLP-1 from mixed colonic cultures via GPR43
in vitro and in vivo (28). Quantitative RT-PCR (qRT-PCR) showed
that Gpr43 and Gpr41 were abundantly expressed in GLP-1-
secreting L-cells. Moreover, SCFAs raised cytosolic Ca2+ through
Gq signaling pathways in L-cells in primary culture. Gpr43- or
Gpr41-knockout mice exhibited reduced SCFA-mediated GLP-1
secretion both in vitro and in vivo and have impaired glucose
tolerance. Additionally, Gpr43-knockout mice exhibited reduc-
tion of insulin secretion in accompaniment with the reduction
of in vivo glucose-stimulated GLP-1 secretion (28). However, to
determine the effects of SCFAs on the secretion of gut hormones,
the expression and function of GPR41, and GPR43 in subtypes of
enteroendocrine cells, such as L-cells and K-cells, must be charac-
terized in detail using Gpr41- and Gpr43-double-knockout mice.
Thus, pharmacological manipulation of appetite using a GPR43
agonist may be useful for treatment of obesity. Moreover, these
types of studies may provide essential information concerning
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the role of GLP-1 in insulin secretion in patients with type-2
diabetes. The anorexigenic neural circuits are subsequently acti-
vated via PYY and GLP-1, reducing food intake and increasing
energy expenditure. Hence, regulation of PYY and GLP-1 secre-
tion via GPR43 maintains energy homeostasis and may be a valid
approach for treating metabolic disorders.
CONCLUSION
GPR43 regulates metabolic rate when activated by SCFAs that are
produced by gut microbiota in a variety of host tissues (Figure 1).
Future studies are expected to reveal the presence of a central
mechanism that mediates the effects of diet and probiotics on
human homeostasis. Additionally, GPR43 may represent a promis-
ing therapeutic target for the treatment of metabolic syndromes,
such as obesity and diabetes.
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